Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2022-03-14 00:00:00 ET · period of report 2022-03-10 · accession 0001104659-22-033390 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-14 | 2022-03-10 | APRE | Attar Eyal C. | SVP, Chief Medical Off, Dir | A - Grant | $0.00 | +42.9K | 89.9K | +91% | $0 |
| D | 2022-03-14 | 2022-03-10 | APRE | Attar Eyal C. | SVP, Chief Medical Off, Dir | A - Grant | $0.00 | +185.9K | 185.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-10 | A | A | 42,900 | $0.00 | 89,900 | D | — | — | (F1) These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| 2 | Derivative | Stock Option (right to Buy) | 2022-03-10 | A | A | 185,900 | $0.00 | 185,900 | D | $1.82 · — to 2032-03-10 | 185,900 Common Stock | (F2) Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |